Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis

AIM: To determine the efficacy and safety of certolizumab pegol for the treatment of rheumatoid arthritis in a real-world setting. MATERIALS & METHODS: Patients with moderate-to-severe rheumatoid arthritis who initiated therapy with certolizumab were followed for 12 weeks. Response was assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Soriano, Enrique R, Dellepiane, Analia, Salvatierra, Gabriela, Benítez, Cristian Alejandro, Salinas, Rodrigo Garcia, Baruzzo, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905631/
https://www.ncbi.nlm.nih.gov/pubmed/29682324
http://dx.doi.org/10.4155/fsoa-2017-0149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905631/
https://www.ncbi.nlm.nih.gov/pubmed/29682324
http://dx.doi.org/10.4155/fsoa-2017-0149

Ejemplares similares